Sponsored by:
General Motors (GM)
General Electric (GE)
Apple (AAPL)
Deere (DE)
Focus Stocks
Featured Stories
S&P Indices Announces Changes to U.S. Indices
Staples, Inc. Announces First Quarter 2012 Performance
Xerox Broke Support
Are the Bears Taking Control over F5 Networks?
Chico's FAS Reports First Quarter Earnings
Earnings Preview: Medtronic
Published on Monday, 21 November 2011 12:04 Written by Danny Miller
New York, November 21st (TradersHuddle.com) - Shares of Medtronic, Inc. (NYSE:MDT) are trading lower by -1.80% ahead of its
quarterly earnings release. Medtronic, the maker of therapeutic and diagnostic medical products is expected to release its quarterly results on November 22nd.
Wall Street Analysts consensus calls for a profit of $0.82 a share on $4.07 billion revenue.
Medtronic estimates have a range of $0.05 a share. The high estimate calls for profit of $0.84 a share and the low estimate is calling for a profit of $0.79 a share, a year ago for the quarter the company reported $0.82 a share.
Medtronic, Inc. (NYSE:MDT) develops therapeutic and diagnostic medical products. Its principal products include those for bradycardia pacing, tachyarrhythmia management, atrial fibrillation management, heart failure management, heart valve replacement, malignant and non-malignant pain, and movement disorders.
Other companies on the watch on this earnings event are Stryker Corporation NYSE:SYK and Edwards Lifesciences Corporation NYSE:EW.
Related Articles
- Women Undergoing TAVI Using the Medtronic CoreValve® System Have Similar Survival Benefit as Men
- Medtronic Receives Notification That U.S. Department of Justice and U.S. Attorney’s Office Have Closed Their Investigation of Activities Relating to INFUSE(R) Bone Graft
- CORRECTING and REPLACING Medtronic IN.PACT Drug-Eluting Balloon Studies Show Significant Benefit of Novel Medical Device in Treating Narrowed Arteries
- Studies of Medtronic IN.PACT Drug-Eluting Balloons Show Significant Benefit in Peripheral and Coronary Arteries
- Medtronic Nets New Indications for Resolute Integrity Drug-Eluting Stent in Europe
- Medtronic Announces 2012 Analyst Meeting and Webcast
- Medtronic to Announce Financial Results for Its Fourth Quarter and Fiscal Year 2012
- Study Shows Longer Arrhythmia Detection Window Reduces Shocks for Medtronic Implantable Defibrillator Patients
- Medtronic Expands Availability of Valiant(R) Captivia(R) Stent Graft in Major Global Markets
- Eighteen North Suburban High School Graduates Named 2012 Medtronic Scholars
Related Partner Headlines
- Medtronic Receives Notification That U.S. Department of Justice and U.S. Attorney's Office Have Closed Their Investigation of Activities Relating to INFUSE Bone Graft - Benzinga
- Medtronic Nets New Indications for Resolute Integrity Drug-Eluting Stent in Europe - Benzinga
- UPDATE: Citigroup Maintains Buy Rating, Lowers PT for Medtronic - Benzinga
- Medtronic Inc. (MDT): Today's Featured Health Services Loser - TheStreet.com
- Medtronic Inc. (MDT): Today's Featured Health Services Winner - TheStreet.com
- Medtronic Stock To Go Ex-dividend Tomorrow (MDT) - TheStreet.com
- UPDATE: Brean Murray Carret Raises Target on Medtronic to $47 - Benzinga
- Piper Jaffray Reiterates Overweight, $40 Target on Medtronic - Benzinga
- JP Morgan Maintains Neutral on Medtronic - Benzinga
- Morgan Stanley: Medtronic Shows Weakness Where Expected - Benzinga
Real Money Pro from TheStreet: Headlined by legendary hedge fund manager Doug Kass, our team of market technicians and professional traders hand you unique perspectives and breakthrough investment opportunities.
Access this exciting service -- Real Money Pro -- FREE, right now!
TradersHuddle Search
| Sponsored By:
|
|
Stock Search: |
|
Site Search: Loading
|
Latest Partner Headlines
Stock Market
Loading
